1.82
1.68%
+0.03
PMV Pharmaceuticals Inc stock is currently priced at $1.82, with a 24-hour trading volume of 455.94K.
It has seen a +1.68% increased in the last 24 hours and a +1.11% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.78 pivot point. If it approaches the $1.84 resistance level, significant changes may occur.
Previous Close:
$1.79
Open:
$1.79
24h Volume:
455.94K
Market Cap:
$93.63M
Revenue:
-
Net Income/Loss:
$-68.96M
P/E Ratio:
-1.1166
EPS:
-1.63
Net Cash Flow:
$-56.62M
1W Performance:
-10.78%
1M Performance:
+1.11%
6M Performance:
-20.52%
1Y Performance:
-65.98%
PMV Pharmaceuticals Inc Stock (PMVP) Company Profile
Name
PMV Pharmaceuticals Inc
Sector
Industry
Phone
609 642 6670
Address
8 Clarke Drive, Suite 3, Cranbury
PMV Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
Sep-22-21 | Upgrade | Goldman | Neutral → Buy |
Aug-19-21 | Initiated | Oppenheimer | Perform |
Aug-02-21 | Initiated | Guggenheim | Buy |
Jul-29-21 | Initiated | H.C. Wainwright | Buy |
Oct-20-20 | Initiated | BofA Securities | Buy |
Oct-20-20 | Initiated | Cowen | Outperform |
Oct-20-20 | Initiated | Evercore ISI | Outperform |
Oct-20-20 | Initiated | Goldman | Neutral |
View All
PMV Pharmaceuticals Inc Stock (PMVP) Latest News
PMV Pharmaceuticals (NASDAQ:PMVP) Given Buy Rating at HC Wainwright - Defense World
Defense World
PMV Pharmaceuticals (NASDAQ:PMVP) Receives "Buy" Rating from HC Wainwright - MarketBeat
MarketBeat
Ratio Review: Analyzing PMV Pharmaceuticals Inc (PMVP)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex
The Dwinnex
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June - GlobeNewswire
GlobeNewswire
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June - Yahoo Canada Finance
Yahoo Canada Finance
Foundation Medicine, PMV Pharma partner on cancer diagnostic By Investing.com - Investing.com
Investing.com
PMV Pharmaceuticals Inc Stock (PMVP) Financials Data
PMV Pharmaceuticals Inc (PMVP) Net Income 2024
PMVP net income (TTM) was -$68.96 million for the quarter ending December 31, 2023, a +5.94% increase year-over-year.
PMV Pharmaceuticals Inc (PMVP) Cash Flow 2024
PMVP recorded a free cash flow (TTM) of -$56.62 million for the quarter ending December 31, 2023, a +21.08% increase year-over-year.
PMV Pharmaceuticals Inc (PMVP) Earnings per Share 2024
PMVP earnings per share (TTM) was -$1.45 for the quarter ending December 31, 2023, a +10.49% growth year-over-year.
PMV Pharmaceuticals Inc Stock (PMVP) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Mack David Henry | President and CEO |
Oct 18 '23 |
Option Exercise |
0.53 |
198,407 |
105,156 |
363,877 |
Alland Leila | Chief Medical Officer |
Sep 15 '23 |
Sale |
6.62 |
6,291 |
41,646 |
45,909 |
Jalota Deepika | Chief Development Officer |
Sep 15 '23 |
Sale |
6.62 |
4,104 |
27,168 |
29,946 |
Mack David Henry | President and CEO |
Aug 07 '23 |
Option Exercise |
0.53 |
85,500 |
45,315 |
165,470 |
About PMV Pharmaceuticals Inc
PMV Pharmaceuticals, Inc., a precision oncology company, discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. Its lead product candidate is PC14586, a small molecule that corrects and restores p53 function. The company also develops product candidates for p53 R273H hotspot mutation and other p53 hotspot mutations. PMV Pharmaceuticals, Inc. was formerly known as PJ Pharmaceuticals, Inc. and changed to in July 2013. The company was founded in 2013 and is headquartered in Cranbury, New Jersey.
Cap:
|
Volume (24h):